Alexandra Calmy

Dados Biográficos

ID7734240
NOMEAlexandra Calmy
PRENOMESAlexandra
SOBRENOMECalmy
ASSINATURACALMY A
AFILIAÇÕESUniversity Hospital of Geneva
ORCID0000-0002-1137-6826
VERIFICADOSim
TOTAL DE OBRAS7
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR7
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2010
ANO MAIS RECENTE DE PUBLICAÇÃO2025
ÍNDICE H0

  • International healthcare workers’ experiences and perceptions of the 2022 multi-country mpox outbreak

    Open AccessVanessa Apea, Boghuma K Titanji et al.ARTICLEPLOS Global Public Health2025

    In May 2022, the most widespread outbreak of sustained transmission of mpox outside of countries historically affected countries in Western and Central Africa occurred. We aimed to examine the personal and clinical experiences of international healthcare workers (HCWs) during this public health emergency. We conducted an international cross-sectional survey study between August and October 2022, examining the experiences and perceptions of HCWs c…

  • Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study

    Open AccessFabio Mauri, Sara Cottler-Casanova et al.ARTICLEJournal of Immigrant and Minority…2022

    FGM/C is a harmful practice that involves injury of the external female genitalia without medical purpose. It is mainly practiced in Africa, Asia, and the Middle East. However, with the migratory flows, women and girls with FGM/C and its consequences live all over the world. The lack of knowledge on how to care for women and girls living with FGM/C extends among all categories of health professionals involved in women's health, including infectio…

  • High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study

    Juliane Schäfer, Jim Young et al.ARTICLEAIDS Care2017

    Physical activity (PA) can improve cardiorespiratory status, strength, body composition and quality of life for patients infected with HIV. Evidence from HIV-uninfected populations also shows that PA is associated with a lower risk of mortality, primarily death due to cardiovascular causes. There is, however, a lack of data on how physically active HIV-infected patients are. In this study, we assessed levels of self-reported PA over time in patie…

  • The first decade of antiretroviral therapy in Africa

    Open AccessNathan Ford, Alexandra Calmy et al.ARTICLEGlobalization and Health2011

    The past decade has seen remarkable progress in increasing access to antiretroviral therapy in resource-limited settings. Early concerns about the cost and complexity of treatment were overcome thanks to the efforts of a global coalition of health providers, activists, academics, and people living with HIV/AIDS, who argued that every effort must be made to ensure access to essential care when millions of lives depended on it. The high cost of tre…

  • Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study

    Open AccessThe Swiss HIV Cohort Study, Olivia Keiser et al.ARTICLEAIDS and Behavior2011

  • When to start antiretroviral therapy in resource-limited settings

    Open AccessNathan Ford, Alexandra Calmy et al.ARTICLEBMC International Health and…2010

    BACKGROUND: Recent evidence from developed and developing countries shows clear clinical and public health benefit to starting antiretroviral therapy (ART) earlier. While discussions about when to start ART have often focused on the clinical risks and benefits, the main issue is one of fair limit-setting. We applied a human rights framework to assess a policy of early treatment initiation according to the following criteria: public-health purpose…

  • Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon

    Open AccessJules Brice Tchatchueng‐Mbougua, Jules B Tchatchueng Mbougua et al.ARTICLEBMC Public Health2010

    This study suggests that the nevirapine-based antiretroviral therapy could be used safely as first-line treatment in patients with low CD4 cell count in Africa despite frequent coinfections with HBV or HCV and infrequent testing of these infections. Although testing for HBV and HCV should be systematically performed before initiating antiretroviral therapy, transaminases elevations at baseline or during treatment should be a decisive argument for…